1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-045, NCT01347333
|
|
2.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 22 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EF-19, NCT01756729
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Pharmaceutical / Industry Protocol IDs: 020221, NCT00045968
|
|
4.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: CE6, CAN-NCIC-CE6, EORTC-26062-22061, TROG 08.02, SPRI-CAN-NCIC-CE.6, CDR0000547163, EORTC-26062, EORTC-22061, NCT00482677
|
|
5.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000582632, EORTC-26053, CAN-NCIC-CEC1, RTOG-0834, EORTC-22054, EUDRACT-2006-001533-17, SPRI-EORTC-26053, MERCK-EORTC-26053, MRC-BR14, COGNO-EORTC-26053, CEC1, NCT00626990
|
|
6.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000640442, NCCTG-N0577, EORTC-26081-22086, EudraCT-2008-007295-14, N0577, NCT00887146
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: YP2008009, NCT00897377
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EF-14, NCT00916409
|
|
9.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000654697, ECOG-E3F05, E3F05, NCT00978458
|
|
10.
|
Phase: Phase III Type: Tissue collection/Repository, Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: CPT-SIOP-2009, NCT01014767
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: CeTeG, 2009-011252-22, NCT01149109
|
|
12.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 50 and under Sponsor: NCI, Other Protocol IDs: AEWS1031, NCI-2011-02611, COG-AEWS1031, CDR0000687639, U10CA098543, NCT01231906
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 50 and over Sponsor: Other Protocol IDs: E33033, NCT01450449
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDX110-04, NCT01480479
|
|
15.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: IRB#10BN132, NCT01502280
|
|
16.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08 TETE 01, NCT01507506
|
|
17.
|
Phase: Phase III Type: Health services research, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: XBR2011022, NCT01479686
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 2012012, NCT01649830
|
|
19.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: LJ-Glioma 3. 3.0 Version, NCT01656980
|
|
20.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225C2301, NCT01708174
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CSNO2012001, NCT01765088
|
|
22.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: P120105, 2012-004536-34, NCT01805453
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-697, NCT01811121
|
|
24.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
|
|
25.
|
Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: OHSU-2868, P30CA069533, 8507, SOL-04058-L, 2868, OHSU-8507, OHSU-SOL-04058-L, NCT00303849
|